Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jeffrey Doi"'
Autor:
Lawrence Kasherman, Jeffrey Doi, Katherine Karakasis, Jeffrey Schiff, Abhijat Kitchlu, Stephanie Lheureux, Amit M. Oza
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 661-670 (2021)
Solid organ transplant recipients on long-term immunosuppressive medication are at increased risk of developing malignancy, and treatment of advanced cancers with angiogenesis inhibitors in this context has not been widely studied. We present a case
Externí odkaz:
https://doaj.org/article/cd2a6aa6e8f14cbca3e659ed04a60424
Publikováno v:
Br J Clin Pharmacol
The development of immune checkpoint inhibitors (ICI) represents a major milestone in immune-oncology. Over the years these agents have demonstrated efficacy in an increasing array of malignancies. Despite this success however, significant challenges
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d543ad787d58af8537da0e156266ac8
https://doi.org/10.1111/bcp.14355
https://doi.org/10.1111/bcp.14355
Autor:
Abdulazeez Salawu, Aaron R. Hansen, Anna Spreafico, Esmail Al-Ezzi, Sheila Webster, Philippe L. Bedard, Jeffrey Doi, Lisa Wang, Lillian L. Siu, Albiruni R. Abdul Razak
Publikováno v:
Targeted oncology. 17(3)
Epidermal growth factor receptor (EGFR)- and human epidermal growth factor receptor (HER)2-targeted therapies are approved for the treatment of breast, gastric/gastrointestinal junction (GEJ), and non-small cell lung cancer (NSCLC) with specific mole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13b31d1ad2d472cb3b76ceee214bd6a1
https://pubmed.ncbi.nlm.nih.gov/35635640
https://pubmed.ncbi.nlm.nih.gov/35635640
Publikováno v:
Cancers
With the advent of checkpoint inhibitor treatment for various cancer types, the optimization of drug selection, pharmacokinetics and biomarker assays is an urgent and as yet unresolved dilemma for clinicians, pharmaceutical companies and researchers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2162c87d7eb0b694ca57e2b576133012
https://doi.org/10.3390/cancers12010038
https://doi.org/10.3390/cancers12010038
Autor:
Simranjot Shokar, Elena Buldo, Aaron R. Hansen, Philippe L. Bedard, Lindsay Carlsson, Anna Spreafico, Lillian L. Siu, Jeffrey Doi
Publikováno v:
Journal of Clinical Oncology. 36:e18551-e18551
e18551Background: Cancer immunotherapy drugs are now approved to treat many types of cancer. Little is known about patient knowledge, attitudes, and expectations of cancer immunotherapies. Methods:...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee58f90b1925c8148a48a921bc56486a
https://doi.org/10.1200/jco.2018.36.15_suppl.e18551
https://doi.org/10.1200/jco.2018.36.15_suppl.e18551